Search clinical trials for: severe COPD

Total 12415 results

NHS Greater Glasgow and Clyde
Queen's University, Belfast

Completed

Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma (MAPLE)

Asthma

United Kingdom
University Medical Center Groningen

Unknown

An Integrative Genomic Approach to Solve tHe Puzzle of sevERe earLy-Onset COPD (SHERLOCk)

Chronic Obstructive Pulmonary Disease | COPD | Severe Early-Onset COPD | SEO-COPD

Netherlands
AstraZeneca

Completed

European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, France, Italy, Spain, Turkey, United Kingdom, Germany, Denmark, Finland, Netherlands, Norway, Austria, Belgium, Portugal, Greece, Ireland, Switzerland
China-Japan Friendship Hospital

Unknown

Extracorporeal Carbon Dioxide Removal in Severe Chronic Obstructive Pulmonary Disease Exacerbation

COPD Exacerbation

China
China-Japan Friendship Hospital

Unknown

Respiratory Support in Severe Chronic Obstructive Pulmonary Disease Exacerbation

COPD Exacerbation

China
Hospital Universitario Reina Sofia de Cordoba
Instituto de Salud Carlos III

Completed

Tobacco Intensive Motivational and Estimate Risk

Smoking Cessation | COPD | Severe Mental Disorder

Spain
ADIR Association
Groupe Hospitalier du Havre; CHU de Rouen - Accueil

Completed

Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

France
Schön Klinik Berchtesgadener Land

Completed

Effects of Whole-Body Vibration Training Versus Balance Training in Patients With Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Pearl Therapeutics, Inc.

Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

COPD

United States
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Germany, Poland, Romania, Hungary, Sweden, Russian Federation, Bulgaria, Finland, Israel, Belgium
Guangzhou Institute of Respiratory Disease

Completed

Efficacy and Mechanism of NIV in Relieving Dyspnea After Exercise in Patients With Stable Severe COPD

Chronic Obstructive Pulmonary Disease | Dyspnea

China
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
AstraZeneca

Completed

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Dayton VA Medical Center

Completed

Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD

Sedation | Dexmedetomidine | COPD

United States
AstraZeneca

Completed

Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients (SECURE2)

Chronic Obstructive Pulmonary Disease (COPD)

China
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
Laval University
Novartis

Completed

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD (RED)

COPD

Canada
AstraZeneca
Parexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaborators

Completed

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)

Chronic Obstructive Pulmonary Disease COPD

United States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
University Hospital, Mahdia

Unknown

Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD

Acute Exacerbation Copd

Tunisia
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
University of Dundee
Tenovus Scotland

Completed

Beta Blocker Therapy in Moderate to Severe COPD (ANDA2)

Chronic Obstructive Pulmonary Disease

United Kingdom
Centre Hospitalier Universitaire de Besancon

Unknown

Ventilatory Adaptation to Concentric Versus Eccentric Exercise in Patients With Severe COPD (CONvEX)

Chronic Obstructive Pulmonary Disease Severe

France
Centre Hospitalier Universitaire de Saint Etienne

Completed

Prevention of Post-exercise Muscle Fatigue and Effect on Exercise Training in Severe Patients With COPD. (QUADRIVEND)

Obstructive Lung Diseases

France
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

COPD

Belgium
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Nuvaira, Inc.

Withdrawn

Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population (DISCOVER TLD)

COPD
Merck Sharp & Dohme LLC

Terminated

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Terminated

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

COPD
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
Henan University of Traditional Chinese Medicine
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Pulmonary Disease, Chronic Obstructive

China
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
AstraZeneca
Menarini Group

Completed

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients (ACTIVATE)

Pulmonary Disease, Chronic Obstructive

Germany, Hungary, Spain, Canada
Fundació Sant Joan de Déu

Unknown

Acupoint Transcutaneous Electrical Nerve Stimulation in Hospitalized COPD Patients With Severe Dyspnoea

Pulmonary Disease, Chronic Obstructive

Spain
University of Pittsburgh
National Institutes of Health (NIH)

Terminated

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

Pulmonary Disease, Chronic Obstructive | Head and Neck Squamous Cell Cancer | Non-Small-Cell Lung Carcinoma

United States
Dayton VA Medical Center

Withdrawn

Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PT009001)

Chronic Obstructive Pulmonary Disease

United States
Spry Health

Completed

Loop Band Validation Study

COPD

United States
Cukurova University

Completed

Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation

Anesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease Mild

Turkey
ResMed

Terminated

A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b (ComfortCOPD)

Chronic Obstructive Pulmonary Disease

Germany
Spiration, Inc.

Completed

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema (IBV®Valve)

Emphysema | COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
VA Office of Research and Development

Completed

An Intervention to Improve Function in Severe Cardiopulmonary Illness

Heart Failure | Chronic Obstructive Pulmonary Disease (COPD)

United States

Search clinical trials for: severe COPD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations